

## Neoflavonoids from the Heartwood of *Dalbergia melanoxylon*

Zhangjun Xu<sup>1</sup>, Yang Liu<sup>1</sup>, Xiaowei Meng<sup>2</sup>, Li Yang<sup>1</sup>, Feng Shao<sup>1</sup>,  
Ronghua Liu<sup>2\*</sup> and Lanying Chen<sup>3\*</sup>

<sup>1</sup> Key Laboratory of Modern Preparation of TCM, Ministry of Education  
Jiangxi University of Chinese Medicine, Nanchang, Jiangxi 330004, P. R. China

<sup>2</sup> The College of Pharmacy, Jiangxi University of Chinese Medicine,  
Nanchang, Jiangxi 330004, P. R. China

<sup>3</sup> National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi  
University of Chinese Medicine,  
Nanchang, Jiangxi 330004, P. R. China

(Received May 10, 2021; Revised June 25, 2021; Accepted June 26, 2021)

**Abstract:** A new neoflavonoid, (1R, 8R, 9R)-pterolinuse K (**1**) and six known neoflavonoids (**2-7**) were obtained from the heartwood of *Dalbergia melanoxylon*. The structure of the new neoflavonoid was elucidated by extensive NMR investigation, and X-ray crystallographic analysis. Compounds **3** and **6** showed anti-inflammatory activity with IC<sub>50</sub> values 23.14 ± 0.30 and 19.46 ± 1.02 μM, respectively. Compounds **2-4**, **6**, **7** were showed cytotoxicity on Caco-2, MDA-MB-468, MDA-MB-231, CT26 cell lines. Moreover, compounds **2**, **4** exhibited the significant activity in MDA-MB-231 cell lines with IC<sub>50</sub> values 7.54 ± 1.50 and 7.23 ± 0.40 μM, respectively.

**Keywords:** *Dalbergia melanoxylon*; neoflavonoids; anti-inflammatory activity; anti-tumor activity. © 2021 ACG Publications. All rights reserved.

### 1. Plant Source

The heartwoods of *Dalbergia melanoxylon* Guill. & Perr. (*D. melanoxylon*) were purchased from Fang Cheng Gang market, Guangxi Province, China, in July 2014 and identified by Professor Feng Xu at the product quality inspection center of Guangxi University. A voucher specimen (No. Liu-20140702) was deposited in the Key Laboratory of Innovation Drug and Efficient Energy-saving Pharmaceutical Equipment, Jiangxi University of Traditional Chinese Medicine.

\* Corresponding author: E- Mail: [rhliu@163.com](mailto:rhliu@163.com) (R. -H. Liu) and [ely5831@163.com](mailto:ely5831@163.com) (L. -Y. Chen)

## 2. Previous Studies

Neoflavonoids were belong to the flavonoids class with the structural of C6-C3-C6, it contains 4-arylcoumarins, 4-arylchromanes, dalbergiones, and dalbergiquinolins [1]. The neoflavonoids were reported to display a variety of pharmacologicalactivities, for example anti-osteoporosis [2], anti-inflammatory [3], anti-tumor [4], anti-androgen [5] and cardioprotective effects [6-9]. *D. melanoxylon* belongs to the family Leguminosae and subfamily Papilionidae, is a heavily branched deciduous tree [10]. It has a wide range of occurrence in sub-Saharan Africa [11]. *D. melanoxylon* have been used for treating abdominal pain, gonorrhoea, joint pain and bronchitis [12-13].


## 3. Present Study

The powdered heartwood of *D. melanoxylon* (50.0 kg) was extracted by infusion with 70% ethanol at roomtemperature (24h, 3 times). Next, the extraction was filtered and the solvent was evaporated under reduced pressure in a rotary evaporation equipment (Buchi, Switzerland). And then, the obtained extract (13.9 kg) was dissolved in distilled H<sub>2</sub>O and successively partitioned with CH<sub>2</sub>Cl<sub>2</sub>, EtOAc and *n*-BuOH. The CH<sub>2</sub>Cl<sub>2</sub> portion (8.5 kg) was subjected to silica gel CC (column chromatography) using petroleum ether-EtOAc (from 50:1 to 1:5, *v/v*) as the elution to yield 22 fractions (Frs.1-Frs.22). Frs.7 (447.4 g) was purified by silica gel column to give six fractions (Frs.7.A-Frs.7.F), through gradient elution with changing ratios of CH<sub>2</sub>Cl<sub>2</sub>-MeOH from 100:1-10:1(*v/v*). Frs.7.C (196.9g) was purified by Sephadex LH-20 CC eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (1:1, *v/v*) to yield three fractions (Frs.7.C.1-Frs.7.C.3). Frs.7.C.2 (7.5 g) was separated by silica gel column (petroleum ether-acetone, 20:1-5:1) to yield **3** (1.7 g). Frs.7.C.3 (7.5 g) was separated by silica gel column (petroleum ether-acetone, 20:1-2:1) to yield **4** (11.2 g). Frs.9 (96.9 g) was fractionated *via* silica gel CC eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (from 400:1-10:1, *v/v*) to yield three fractions (Frs.9.A-Frs.9.C). Frs.9.B (45.8 g) was further fractionated *via* silica gel CC eluted with petroleum ether-acetone (from 10:1-2:1, *v/v*) to obtain **5** (16.1 mg). Frs.13 (227.6 g) was fractionated *via* silica gel CC eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (from 100:1-10:1, *v/v*) to yield three fractions (Frs.13.A-Frs.13.C). Frs.13.B (89.3 g) was further fractionated *via* silica gel CC eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (from 200:1-100:1, *v/v*) to obtain **2** (20.1 g). Frs.14 (303.7 g) was loaded ODS column chromatography with MeOH-H<sub>2</sub>O gradient elution to give (from 30:70 to 50:50, *v/v*) to yield 9 fractions (Frs.14.A-Frs.14.I). Frs.14.C (5.4 g) was further fractionated *via* silica gel CC eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (from 1000:1-100:1, *v/v*) to obtain **6** (56.8 mg). Frs.14.I (23.6 g) was fractionated *via* silica gel CC eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (from 100:1-10:1, *v/v*) to yield 4 fractions (Frs.14.I.1-Frs.14.I.4). Frs.14.I.2 (953.5 mg) was further fractionated *via* silica gel CC eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (from 1000:1-200:1, *v/v*) to obtain **7** (58.2 mg).Frs.15 (83.2 g) was loaded ODS column chromatography with MeOH-H<sub>2</sub>O gradient elution to give (from 30:70 to 50:50, *v/v*) to yield 5 fractions (Frs.15.A-Frs.15.E). Frs.15.A(1.8 g) was purified by Sephadex LH-20 CC eluted with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (1:1, *v/v*) to yield 2 fractions (Frs.15.A.1-Frs.15.A.2). Frs.15.A.1 (452.7 mg) was separated by preparative HPLC eluted with MeOH-H<sub>2</sub>O (32:68, *v/v*) to yield **1** (20.5 mg, *t<sub>R</sub>* = 36.4 min).

(1*R*, 8*R*, 9*R*)-pterolinuse *K* (**1**): Colorless crystals (MeOH);  $[\alpha]_D^{24} = +22.7$  (*c* = 0.1, MeOH). UV (MeOH)  $\lambda_{\max}$ : 290, 250, 240 nm, IR (KBr)  $\nu_{\max}$  3372.2, 1660.1, 1453.1, 1452.9, 1413.3 cm<sup>-1</sup>. CD (MeOH)  $\lambda_{\max}$  ( $\Delta\epsilon$ ) 234 (+1.41), 283 (+1.34); HR-ESI-MS *m/z* 303.1224 ([*M*+*H*]<sup>+</sup> calcd for C<sub>17</sub>H<sub>19</sub>O<sub>5</sub>, 303.1227). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, 600 MHz) and <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>, 150 MHz): see Table S1 in supporting information.

Neoflavonoids from *Dalbergia melanoxylon*


In our ongoing project of the investigation on the chemical constituents and bioactive of *D. melanoxylon*, one new neoflavonoid (**1**) and six known neoflavonoids (**2-7**) were obtained from the heartwood of *D. melanoxylon* (Figure 1).



**Figure 1.** Structures of compounds **1-7**

Compound **1** was a colorless crystals, with a molecular formula of  $C_{17}H_{18}O_5$  as deduced from the (+)-HR-ESI-MS  $m/z$  303.1224 ( $[M+H]^+$  calcd for  $C_{17}H_{19}O_5$ , 303.1227), inferring 9 degree of unsaturation. The  $^1H$ -NMR spectrum exhibited the signals (Table 1) of two hydroxyls at  $\delta_H$  5.89 (1H, s, 1-OH) and 8.93 (1H, s, 5-OH), two methoxy groups at  $\delta_H$  3.62 (3H, s, 12-OCH<sub>3</sub>) and 3.73 (3H, s, 4-OCH<sub>3</sub>), two aromatic protons at  $\delta_H$  7.15 (1H, s, H-3) and 6.51 (1H, s, H-6), four olefinic protons at  $\delta_H$  5.14 (1H, s, H-11), 5.35 (1H, ddd,  $J = 16.9$ , 10.1, 8.1 Hz, H-14), 5.20 (1H, d,  $J = 16.9$  Hz, H-15a) and 5.14 (2H, m, H-15b), two methines at  $\delta_H$  3.68 (1H, t,  $J = 8.1$  Hz, H-8) and 2.83 (1H, s, H-9), diastereotopic methylene protons at  $\delta_H$  2.44 (1H, d,  $J = 12.0$  Hz, H-13a) and 2.15 (1H, d,  $J = 12.0$  Hz, H-13b). Inspection of its  $^{13}C$ -NMR spectra exhibited 17 carbon resonances assignable to two methoxy groups at  $\delta_C$  56.9 (4-OCH<sub>3</sub>) and 56.2 (12-OCH<sub>3</sub>), six aromatic carbons at  $\delta_C$  132.0 (C-2), 109.2 (C-3), 146.4 (C-4), 146.3 (C-5), 115.8 (C-6) and 127.7 (C-7), two double bonds at  $\delta_C$  100.6 (C-11), 183.3 (C-12), 140.0 (C-14) and 117.2 (C-15), four methines at  $\delta_C$  69.5 (C-1), 45.0 (C-8), 48.8 (C-9) and 40.7 (C-13), one conjugated ketone at  $\delta_C$  197.5 (C-10) (Table 1). These data were similar with those of (1*S*, 8*R*, 9*S*)-1, 5-dihydroxy-4,12-dimethoxy-8-vinyl-tricyclo[7.3.1.0<sup>2,7</sup>]trideca-2,4,6,11 tetraen-10-one skeleton [14]. The HMBC correlation of H-13a ( $\delta_H$  2.44) and H-13b ( $\delta_H$  2.15) with C-2 ( $\delta_C$  132.0), C-8 ( $\delta_C$  45.0), C-10 ( $\delta_C$  197.5) and C-12 ( $\delta_C$  183.3) have confirmed the methylene was linked to C-1 ( $\delta_C$  69.5) and C-9 ( $\delta_C$  48.8), two hydroxy groups were attached to C-1 and C-5, respectively. In HMBC spectrum, cross-peaks for 1-OH ( $\delta_H$  5.89)/C-1 ( $\delta_C$  69.5), C-2 ( $\delta_C$  132.0), C-12 ( $\delta_C$  183.3) and C-13 ( $\delta_C$  40.7), 5-OH ( $\delta_H$  5.59)/C-5 ( $\delta_C$  146.3) and C-6 ( $\delta_C$  115.8). 4-OCH<sub>3</sub> ( $\delta_H$  3.73) was located at C-4 ( $\delta_C$  146.4) and 12-OCH<sub>3</sub> ( $\delta_H$  3.62) was located at C-12 ( $\delta_C$  183.3) observed in HMBC and HSQC. The relative configuration was assigned from the ROESY spectrum, in which H-13 [ $\delta_H$  3.68 (1H, t,  $J = 8.1$  Hz)] showed correlation with H-8 suggesting that H-13 [ $\delta_H$  2.44 (1H, d,  $J = 12.0$  Hz), 2.15 (1H, d,  $J = 12.0$  Hz)] was on the same side with H-8 ( $\delta_H$  3.51) (Figure 2). The absolute configuration of compound **1** was also determined to be (1*R*, 8*R*, 9*R*)-pterolinuse K by X-ray crystallography (CCDC: 2052275) (Figure 3).

The six known neoflavonoids (**2-7**) were identified as (*S*)-3'-hydroxy-4,4'-dimethoxydalbergione (**2**) [15], (*S*)-3',4'-dihydroxy-4-methoxydalbergione (**3**) [16], (*S*)-4'-hydroxy-4-methoxydalbergione (**4**) [17], (*S*)-3'-hydroxy-4-methoxydalbergione (**5**) [16], (*S*)-4-methoxydalbergione (**6**) [17], melanoxoin (**7**) [18], by comparing the observed and reported NMR data.



**Figure 2.** Selected HMBC and ROESY correlations of compound **1**

The isolates **1-7** were assessed anti-inflammatory properties against lipopolysaccharide (LPS)-activated RAW 264.7 cells in *vitro* assay. Among all tested compounds, **3** and **6** showed moderate anti-inflammatory activity with  $IC_{50}$  values  $23.14 \pm 0.30$  and  $19.46 \pm 1.02$   $\mu$ M, respectively (Table 2). Compounds **3** and **6** have similar chemical structure and **6** showed better activity, which suggested that the hydroxy group in C-3' and C-4' might weaken the anti-inflammatory activity of neoflavonoids.

**Table 2.** Cytotoxicities and anti-inflammatory activities ( $IC_{50}$  in  $\mu$ M) of compounds

Compound	Cytotoxicity	Anti-inflammatory activity
quercetin	>100	$17.92 \pm 0.92$
<b>1</b>	>100	>100
<b>2</b>	$26.09 \pm 1.99$	-
<b>3</b>	>100	$23.14 \pm 0.30$
<b>4</b>	$22.24 \pm 2.30$	-
<b>5</b>	>100	>100
<b>6</b>	>100	$19.46 \pm 1.02$
<b>7</b>	$98.48 \pm 20.85$	$89.31 \pm 7.51$

**Table 3.** Anti-tumor activities ( $IC_{50}$  in  $\mu$ M) of compounds

Compound	Caco-2	MDA-MB-468	MDA-MB-231	CT26
5-FU	$190.32 \pm 24.13$	$149.09 \pm 21.02$	$48.84 \pm 14.84$	$61.89 \pm 16.35$
<b>1</b>	>100	>100	>100	>100
<b>2</b>	$15.14 \pm 1.13$	$40.90 \pm 7.56$	$7.54 \pm 1.50$	$23.10 \pm 1.20$
<b>3</b>	$26.46 \pm 3.76$	$37.52 \pm 1.70$	$16.60 \pm 2.98$	$52.38 \pm 16.51$
<b>4</b>	$11.42 \pm 1.08$	$23.66 \pm 1.58$	$7.23 \pm 0.40$	$24.43 \pm 0.90$
<b>5</b>	>100	>100	>100	>100
<b>6</b>	$32.92 \pm 2.34$	$89.00 \pm 10.90$	$21.88 \pm 0.63$	>100
<b>7</b>	$46.89 \pm 2.54$	$22.14 \pm 1.07$	$27.31 \pm 1.10$	$33.83 \pm 0.94$

All isolated neoflavonoids (**1-7**) from *D. melanoxylon* were evaluated for their cytotoxic activities on

Neoflavonoids from *Dalbergia melanoxylon*

Caco-2, MDA-MB-231, MDA-MB-468 and CT26 cell lines by MTT assays. The results revealed that compound **2** and **4** showed potent cytotoxic activities against four above cell lines with IC<sub>50</sub> values ranging from 7.23 ± 0.40 to 40.90 ± 7.56 μM, compound **3** and **7** displayed moderate cytotoxic activities against four above cell lines with IC<sub>50</sub> values ranging from 16.60 ± 2.98 to 52.38 ± 16.51 μM (Table 3), which suggested that the hydroxy group might enhance the anti-cancer activity of neoflavonoids. Compounds **2-6** has similar chemical structure but **5** showed no anti-cancer activity. It indicated the hydroxy group in C-3' of **5** might weaken anti-cancer activity.

### Acknowledgments

The work was partially supported by the National Natural Science Foundation of China (81660676 and 81360629), the National Key R&D Program of China (2018YFC1706102) and the Natural Science Foundation of Jiangxi Province (20202BABL216074).

### Supporting Information

Supporting Information accompanies this paper on <http://www.acgpubs.org/journal/records-of-natural-products>

### ORCID

Zhangjun Xu: [0000-0002-8430-0806](https://orcid.org/0000-0002-8430-0806)

Yang Liu: [0000-0002-0959-3004](https://orcid.org/0000-0002-0959-3004)

Xiaowei Meng: [0000-0003-2956-8460](https://orcid.org/0000-0003-2956-8460)

Li Yang: [0000-0001-9098-694X](https://orcid.org/0000-0001-9098-694X)

Feng Shao: [0000-0002-4306-6451](https://orcid.org/0000-0002-4306-6451)

Ronghua Liu: [0000-0001-5623-9000](https://orcid.org/0000-0001-5623-9000)

Lanying Chen: [0000-0001-8115-8114](https://orcid.org/0000-0001-8115-8114)

### References

- [1] M. M. Garazd, Y. L. Garazd and V. P. Khilya (2003). Neoflavones.1. Natural distribution and spectral and biological properties, *Chem. Nat. Compd.* **39**, 54 - 121.
- [2] P. Kumar, P. Kushwaha, V. Khedgikar, J. Gautam, D. Choudhary, D. Singh, R. Trivedi and R. Maurya (2014). Neoflavonoids as potential osteogenic agents from *Dalbergia sissoo* heartwood, *Bioorg. Med. Chem. Lett.* **24**, 2664 - 2668.
- [3] C. Lee, J. W. Lee, Q. Jin, D. S. Jang, S. Lee, D. Lee, J. T. Hong, Y. Kim, M. K. Lee and B. Y. Hwang (2013). Inhibitory constituents of the heartwood of *Dalbergia odorifera* on nitric oxide production in RAW 264.7 macrophages, *Bioorg. Med. Chem. Lett.* **23**, 4263 - 4266.
- [4] K. R. Park, H. M. Yun, T. H. Quang, H. Oh, D. S. Lee, Q. S. Auh and E. C. Kim (2016). 4-Methoxydalbergione suppresses growth and induces apoptosis in human osteosarcoma cells *in vitro* and *in vivo* xenograft model through down-regulation of the JAK2/STAT3 pathway, *Oncotarget* **7**, 6960 - 6971.

- [5] M. Kuroyanagi, A. Ueno, Y. Hirayama, Y. Hirayama, T. Gokita, T. Isiiimaru, S. Kameyama, T. Yanagawa, M. Satake and S. Satake (1996). Anti-androgen active constituents from *Dalbergia cochinchinensis* PIERRE, *Nat. Medicin.* **50**, 408 - 412.
- [6] Y. Liu, N. Zhang, J. W. He, L. Y. Chen, L. Yang, X. W. Meng, F. Shao and R. H. Liu (2021), Two new compounds from the heartwood of *Dalbergia melanoxylon* and their protective effect on hypoxia/reoxygenation injury in H9c2, *Nat. Prod. Commun.* **16**, 1 -7.
- [7] X. X. Lai, N. Zhang, L. Y. Chen, Y. Y. Luo, B. Y. Shou, X. X. Xie and R. H. Liu (2020), Latifolin protects against myocardial infarction by alleviating myocardial inflammatory via the HIF-1  $\alpha$  /NF-  $\kappa$  B/IL-6 pathway, *Pharm. Biol.* **58**, 1156 - 1166.
- [8] N. Zhang, B. Y. Shou, L. Y. Chen, X. X. Lai, Y. Y. Luo, X. W. Meng and R. H. Liu (2020), Cardioprotective effects of latifolin against doxorubicin-induced cardiotoxicity by macrophage polarization in mice, *J. Cardiovasc. Pharmacol.* **75**, 564 - 572.
- [9] Y. Liu, J. C. Shu, M. F. Wang, Z. J. Xu, L. Yang, X. W. Meng, W. B. Duan, N. Zhang, F. Shao, R. H. Liu and L. Y. Chen (2021), Melanoxylonin A-G, neoflavonoids from the heartwood of *Dalbergia melanoxylon* and their cardioprotective effects, *Phytochemistry* **189**, 112845.
- [10] M. Jenkins, S. Oldfield and T. Aylett (2002). International trade in African blackwood, *Cambridge, UK: Fauna and Flora International*.
- [11] R. E. Malimbwi, E. J. Luoga, O. Hofstad, A. G. Mugasha and J. S. Valen (2000). Prevalence and standing volume of *Dalbergia melanoxylon* in coastal and inland sites of Southern Tanzania, *J. Trop. For. Sci.* **12**, 336 - 347.
- [12] P. Mutai, M. Heydenreich, G. Thoithi, G. Mugumbate, K. Chibale and A. Yenesew (2013), 3-Hydroxyisoflavanones from the stem bark of *Dalbergia melanoxylon*: Isolation, antimycobacterial evaluation and molecular docking studies, *Phytochem. Lett.* **6**, 671 - 675.
- [13] P. G. Kareru, A. N. Gachanja, J. M. Keriko and G. M. Kenji, (2008). Antimicrobial activity of some medicinal plants used by herbalists in Eastern province, Kenya, *Afr. J. Trad. CAM.* **5**, 51 - 55.
- [14] M. F. Wang, G. Q. Ma, F. Shao, R. H. Liu, L. Y. Chen, Y. Liu, L. Yang and X. W. Meng (2020). Neoflavonoids from the heartwood of *Dalbergia melanoxylon*, *Nat. Prod. Res.* **16**, 1 - 7. DOI: 10.1080/14786419.2020.1800692
- [15] S. F. Wu, F. R. Chang, S. Y. Wang, T. L. Hwang, C. L. Lee, S. L. Chen, C. C. Wu and Y. C. Wu (2011). Anti-inflammatory and cytotoxic neoflavonoids and benzofurans from *Pterocarpus santalinus*, *J. Nat. Prod.* **74**, 989 - 996.
- [16] S. P. Shrestha, Y. Narukawa and T. Takeda (2007). Chemical constituents of Nepalese propolis: isolation of new dalbergiones and related compounds, *J. Nat. Med.* **61**, 73 - 76.
- [17] W. B. Eyton, W. D. Ollis, I. O. Sutherland, O. R. Gottlieb, M. T. Magalhaes and L. M. Jackman (1965). The neoflavanoid group of natural products-I: Dalbegiones-A new class of quinones, *Tetrahedron* **21**, 2683 - 2696.
- [18] V. Pathak, O. Shirota, S. Sekita, Y. Hirayama, Y. Hakamata, T. Hayashi, T. Yanagawa and M. Satake (1997). Antiandrogenic phenolic constituents from *Dalbergiaco chinchinensis*, *Phytochemistry* **46**, 1219 - 1223.